520 related articles for article (PubMed ID: 10822385)
1. Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release.
Hermisson M; Wagenknecht B; Wolburg H; Glaser T; Dichgans J; Weller M
Oncogene; 2000 May; 19(19):2338-45. PubMed ID: 10822385
[TBL] [Abstract][Full Text] [Related]
2. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
3. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
4. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing.
Wagenknecht B; Schulz JB; Gulbins E; Weller M
Cell Death Differ; 1998 Oct; 5(10):894-900. PubMed ID: 10203695
[TBL] [Abstract][Full Text] [Related]
5. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
Fulda S; Meyer E; Debatin KM
Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
[TBL] [Abstract][Full Text] [Related]
6. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells.
Glaser T; Wagenknecht B; Weller M
Oncogene; 2001 Aug; 20(35):4757-67. PubMed ID: 11521188
[TBL] [Abstract][Full Text] [Related]
7. C2-ceramide signaling in glioma cells: synergistic enhancement of CD95-mediated, caspase-dependent apoptosis.
Wagenknecht B; Roth W; Gulbins E; Wolburg H; Weller M
Cell Death Differ; 2001 Jun; 8(6):595-602. PubMed ID: 11536010
[TBL] [Abstract][Full Text] [Related]
8. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
Walczak H; Bouchon A; Stahl H; Krammer PH
Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456
[TBL] [Abstract][Full Text] [Related]
11. Synthetic 1,4-anthracenedione analogs induce cytochrome c release, caspase-9, -3, and -8 activities, poly(ADP-ribose) polymerase-1 cleavage and internucleosomal DNA fragmentation in HL-60 cells by a mechanism which involves caspase-2 activation but not Fas signaling.
Perchellet EM; Wang Y; Weber RL; Sperfslage BJ; Lou K; Crossland J; Hua DH; Perchellet JP
Biochem Pharmacol; 2004 Feb; 67(3):523-37. PubMed ID: 15037204
[TBL] [Abstract][Full Text] [Related]
12. CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity.
Steinbach JP; Supra P; Huang HJ; Cavenee WK; Weller M
Brain Pathol; 2002 Jan; 12(1):12-20. PubMed ID: 11770895
[TBL] [Abstract][Full Text] [Related]
13. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.
Sun SY; Yue P; Zhou JY; Wang Y; Choi Kim HR; Lotan R; Wu GS
Biochem Biophys Res Commun; 2001 Jan; 280(3):788-97. PubMed ID: 11162590
[TBL] [Abstract][Full Text] [Related]
15. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
Suliman A; Lam A; Datta R; Srivastava RK
Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196
[TBL] [Abstract][Full Text] [Related]
16. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA
Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097
[TBL] [Abstract][Full Text] [Related]
17. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.
Kim EJ; Suliman A; Lam A; Srivastava RK
Int J Oncol; 2001 Jan; 18(1):187-94. PubMed ID: 11115558
[TBL] [Abstract][Full Text] [Related]
18. Bax membrane insertion during Fas(CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2.
Murphy KM; Streips UN; Lock RB
Oncogene; 1999 Oct; 18(44):5991-9. PubMed ID: 10557088
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Winter S; Weller M
J Pharmacol Exp Ther; 1998 Sep; 286(3):1374-82. PubMed ID: 9732400
[TBL] [Abstract][Full Text] [Related]
20. Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells.
Glaser T; Wagenknecht B; Groscurth P; Krammer PH; Weller M
Oncogene; 1999 Sep; 18(36):5044-53. PubMed ID: 10490841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
